Deciphera pharmaceuticals, inc. (DCPH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Net loss

-72,800

-67,256

-56,156

-21,460

-47,384

-32,299

-24,435

-21,690

-21,430

-19,912

-12,038

-10,625

-7,709

Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation expense

6,994

5,345

4,729

4,107

6,229

2,805

2,614

2,232

2,037

2,844

1,012

594

416

Depreciation expense

460

415

169

112

104

82

88

74

56

99

39

31

31

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

0

-4

-2

-4

Net accretion of discounts on marketable securities

1,532

1,729

973

811

486

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,853

9,894

1,690

1,907

-3,170

2,539

2,438

980

-187

832

16

-82

-129

Operating lease assets

-528

-525

-96

-194

-143

-

-

-

-

-

-

-

-

Accounts payable

-8,511

4,400

870

2,963

2,629

2,257

-491

1,083

1,142

1,465

993

1,443

-997

Accrued expenses and other current liabilities

-6,800

12,151

4,799

4,602

2,637

2,640

-435

953

1,319

-

-

-

-

Operating lease liabilities

-555

127

-97

-201

-148

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

698

Other long-term liabilities

0

13

102

135

100

169

165

39

-5

-5

2

5

11

Net cash flows used in operating activities

-80,370

-55,833

-23,191

-37,266

-33,006

-26,868

-24,932

-18,289

-16,694

-12,753

-8,866

-7,666

-7,417

Cash flows from investing activities:
Purchases of marketable securities

203,527

198,952

364,431

74,152

179,607

-

-

-

-

-

-

-

-

Maturities of marketable securities

203,120

-

72,587

87,052

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

669

1,725

2,966

203

41

303

216

455

151

130

202

40

34

Increase in restricted investments

614

0

0

441

0

-

-

-

-

-

-

-

-

Net cash flows used in investing activities

-1,690

1,680

-294,810

12,256

-179,648

-303

-216

-1,524

-151

-130

-202

-40

-34

Cash flows from financing activities:
Proceeds from public offerings, net of underwriting discounts and commissions

189,175

-

-

-

0

-

-

-

-

-

-

-

-

Repayment of notes payable to related party

0

1,154

47

62

31

47

47

47

46

47

47

47

46

Payments of public offering costs

352

-

-

-

0

-

-

-

-

1,577

2,486

327

5

Proceeds from exercise of stock options

2,569

2,182

2,476

81

1,149

107

91

707

10

-

-

-

-

Net cash flows provided by financing activities

191,392

761

434,476

19

1,118

60

-504

186,467

-36

127,488

-2,775

51,739

-51

Net increase (decrease) in cash and cash equivalents

109,332

-53,392

116,475

-24,991

-211,536

-27,111

-25,652

166,654

-16,881

114,605

-11,843

44,033

-7,502

Supplemental disclosure of cash flow information:
Cash paid for interest

0

12

17

25

13

20

21

21

22

23

23

24

25

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities

152

-

-

-

0

-

-

-

97

-

-

-

-

Offering costs included in accounts payable and accrued expenses and other current liabilities

438

-

-

-

0

-

-

-

-

-1,394

-305

1,449

250